RIPK1 Kinase Activity (Ser166): Regulatory Mechanisms and Functions in TNFR1 Signaling

Concept
Receptor-Interacting Protein Kinase 1 (RIPK1) is a multifunctional serine/threonine kinase that acts as a central molecular switch in Tumor Necrosis Factor Receptor 1 (TNFR1) signaling—one of the most critical pathways governing cell survival, inflammatory responses, and programmed cell death (apoptosis and necroptosis). RIPK1’s functional duality is tightly controlled by its kinase activity, which is dynamically regulated through post-translational modifications, with Ser166 autophosphorylation serving as the definitive molecular marker of its activation. In the TNFR1 signaling cascade, RIPK1 transitions from a scaffold protein that promotes cell survival and inflammation (when kinase activity is suppressed) to a death-inducing kinase that triggers apoptosis or necroptosis (when Ser166 phosphorylation is activated). This functional switch is precisely modulated by phosphorylation and ubiquitination events, making RIPK1 (Ser166) a key target for studying signal transduction, cell fate determination, and inflammatory disease pathogenesis.

Research Frontier
Contemporary research on RIPK1 (Ser166) and TNFR1 signaling is advancing at the intersection of cell biology, immunology, and translational medicine, with four key frontier directions driving innovative discovery and therapeutic development:
1. Cell-Type-Specific RIPK1 Regulation: Elucidating how RIPK1 (Ser166) phosphorylation and functional outcomes (survival, apoptosis, necroptosis) vary across cell types (immune cells, epithelial cells, neurons) and disease contexts, uncovering tissue-specific regulatory networks that govern TNFR1 signaling.
2. Post-Translational Modification Crosstalk: Deciphering the dynamic interplay between RIPK1 phosphorylation (Ser166, Ser25, Ser320/335) and ubiquitination (K63-, M1-, K48-linked chains) in fine-tuning kinase activity, and identifying novel modifying enzymes that regulate RIPK1’s functional switch.
3. RIPK1-Targeted Therapeutic Development: Optimizing highly selective RIPK1 kinase inhibitors for the treatment of inflammation- and necroptosis-related diseases (e.g., amyotrophic lateral sclerosis, rheumatoid arthritis, ulcerative colitis) and exploring combination therapies that target RIPK1 in conjunction with other cell death or inflammatory pathways.
4. Translational Biomarker Validation: Validating RIPK1 (Ser166) phosphorylation as a clinical biomarker for disease activity and treatment response in inflammatory and neurodegenerative diseases, and developing non-invasive detection methods for monitoring RIPK1 inhibitor efficacy.
Cutting-edge studies also focus on the role of RIPK1 (Ser166) in pathogen-host interactions, as pathogens often modulate RIPK1 activity to evade host defense mechanisms, and the potential of RIPK1 as a target for infectious disease therapy.

Research Significance
In-depth investigation of RIPK1 (Ser166) kinase activity and its regulatory mechanisms in TNFR1 signaling holds profound scientific and translational significance for cell biology, immunology, and clinical medicine:
· Cell Fate Determination Biology: Uncovering the precise regulation of RIPK1’s functional switch (scaffold vs. death kinase) deepens our understanding of how cells integrate extracellular signals to make survival or death decisions, providing a paradigm for studying signal transduction network dynamics.
· Inflammatory Disease Pathogenesis: RIPK1 (Ser166) activation is a key driver of chronic inflammation and tissue damage in numerous diseases. Elucidating its role in TNFR1 signaling identifies novel molecular targets for treating inflammatory and autoimmune disorders, addressing unmet clinical needs for patients with refractory diseases.
· Therapeutic Innovation for Necroptosis-Related Diseases: Targeting RIPK1 (Ser166) kinase activity with selective inhibitors offers a new therapeutic strategy for diseases driven by excessive necroptosis (e.g., ischemia-reperfusion injury, neurodegeneration), which are often unresponsive to traditional anti-inflammatory or apoptotic inhibitor therapies.
· Infectious Disease Research: Understanding how pathogens manipulate RIPK1 (Ser166) phosphorylation to evade host immunity provides new insights into host-pathogen interactions and enables the development of therapies that restore RIPK1-mediated cell death to clear infections.

TNFR1 Signaling Initiation and RIPK1’s Scaffold Function
The TNFR1 signaling pathway is initiated by the binding of Tumor Necrosis Factor (TNF) to TNFR1, triggering the rapid assembly of signaling complex I at the cell membrane—a multi-protein complex that dictates the initial cell survival and inflammatory response:
1. Composition of Complex I: Complex I consists of adaptor proteins (TRADD, RIPK1, TRAF2), E3 ubiquitin ligases (cIAP1/2, LUBAC), and other regulatory molecules. RIPK1 serves as a central scaffold within this complex, facilitating the recruitment and activation of downstream signaling components.
2. Ubiquitination-Mediated Signaling Activation: Within complex I, RIPK1 and other components are modified with K63- and M1-linked ubiquitin chains, which act as molecular scaffolds to recruit and activate the TAK1-TAB2/3 kinase complex and the IKK complex (IKKα/β-NEMO).
3. Survival and Inflammatory Signal Output: Activation of TAK1 and IKK complexes leads to the downstream activation of the NF-κB signaling pathway, which promotes the transcription of pro-survival proteins (e.g., c-FLIP) and pro-inflammatory cytokines (e.g., TNF-α, IL-6). At this stage, RIPK1’s kinase activity is strictly suppressed by inhibitory phosphorylations, and its primary function is to support signal transduction as a scaffold protein.

Precise Regulation of RIPK1 Kinase Activity: Phosphorylation and Ubiquitination
RIPK1’s kinase activity (marked by Ser166 autophosphorylation) is tightly controlled by a balance of inhibitory and activating post-translational modifications, ensuring that RIPK1 only switches to a death kinase when TNFR1 signaling is dysregulated:
1. Inhibitory Phosphorylations Block RIPK1 Activation:
o Kinases recruited to complex I (e.g., IKKβ, TBK1) directly phosphorylate RIPK1 at Ser25, blocking its ATP-binding pocket and inhibiting kinase activity.
o Downstream kinases activated by TAK1 (e.g., p38/MK2) phosphorylate RIPK1 at Ser320/Ser335, preventing Ser166 autophosphorylation—the critical event for RIPK1 kinase activation.
These inhibitory phosphorylations collectively maintain RIPK1 in a scaffold-only state, promoting cell survival and inflammation.
2. Ubiquitination Regulates RIPK1 Stability and Function:
o Activating Ubiquitination: K63- and M1-linked ubiquitin chains on RIPK1 enhance its scaffolding function, promoting the recruitment of downstream signaling complexes and reinforcing survival/inflammatory signals.
o Inhibitory Ubiquitination: When signal termination is required, K48-linked ubiquitin chains target RIPK1 for proteasomal degradation. Additionally, M1-linked ubiquitin chains recruit autophagy-related proteins (e.g., ATG9, FIP200), leading to RIPK1 clearance via the autophagy-lysosome pathway. These degradation mechanisms prevent abnormal RIPK1 accumulation and unintended activation.

RIPK1 Kinase Activation (Ser166): Triggering Apoptosis and Necroptosis
When inhibitory signals from complex I (phosphorylation or ubiquitination) are compromised—due to genetic mutations, pathogen interference, or pharmacological inhibition—RIPK1’s kinase activity is unleashed, leading to the dissociation of complex I from the membrane and the formation of cytoplasmic complex II. The composition of complex II, combined with RIPK1’s Ser166 phosphorylation status, determines whether the cell undergoes apoptosis or necroptosis:
1. Apoptosis Induction:
• When RIPK1 is activated (Ser166-phosphorylated) and cellular levels of the pro-survival protein c-FLIP are insufficient, complex II (composed of RIPK1, FADD, and caspase-8) promotes the formation of active caspase-8 homodimers.
• Active caspase-8 cleaves and activates downstream caspases (e.g., caspase-3), executing classical apoptotic cell death—a non-inflammatory form of programmed cell death.
2. Necroptosis Induction:
• When caspase-8 activity is inhibited (by viral proteins, genetic mutations, or pharmacological agents), activated RIPK1 (Ser166-phosphorylated) binds to RIPK3, forming a multi-protein complex called the necrosome.
• RIPK1 phosphorylates and activates RIPK3, which in turn phosphorylates its substrate MLKL. Phosphorylated MLKL oligomerizes and translocates to the cell membrane, disrupting membrane integrity and triggering necroptosis—an inflammatory form of programmed cell death that releases pro-inflammatory cytokines to recruit immune cells.

RIPK1 (Ser166) Antibody: A Core Tool for TNFR1 Signaling and Cell Death Research
A highly specific phospho-RIPK1 (Ser166) recombinant monoclonal antibody is an indispensable research tool for studying RIPK1’s regulatory mechanisms, TNFR1 signaling, and cell death pathways, with three core applications in basic and translational research:
1. Mechanistic Studies of RIPK1 Activation: The antibody enables precise monitoring of RIPK1 (Ser166) phosphorylation kinetics under different stimuli (TNF-α, pathogen infection) or genetic backgrounds, elucidating the upstream regulatory pathways that control RIPK1’s functional switch and its downstream effects on cell fate.
2. Pharmacodynamic Evaluation of RIPK1 Inhibitors: In cellular and animal models, the antibody serves as a key pharmacodynamic biomarker to validate the efficacy of RIPK1 kinase inhibitors, confirming whether the drug effectively blocks Ser166 phosphorylation and inhibits RIPK1-mediated cell death.
3. Disease Biomarker Research: The antibody can be used to detect abnormal RIPK1 (Ser166) activation in pathological tissues (e.g., inflammatory lesions, tumor microenvironments), exploring its correlation with disease progression and severity to support precision medicine strategies.

Product Application: ANT BIO PTE. LTD. Reagents for RIPK1 and TNFR1 Signaling Research
As a leading provider of life science research reagents, ANT BIO PTE. LTD. offers a portfolio of high-performance Phospho-RIPK1 (Ser166) Recombinant Rabbit Monoclonal Antibodies under its STARTER sub-brand—its specialized antibody division. Developed via advanced recombinant rabbit monoclonal antibody technology and rigorously validated across Western Blot (WB) and immunofluorescence (IF) platforms, these antibodies are gold-standard tools for detecting RIPK1 kinase activation, supporting cutting-edge research in TNFR1 signaling, necroptosis, inflammation, and infectious diseases.

Core Product Portfolio Advantages
· Ultra-High Phosphorylation Site Specificity: Precisely recognizes RIPK1 phosphorylation at Ser166, the definitive marker of RIPK1 kinase activation, with no cross-reactivity to non-phosphorylated RIPK1 or other phosphorylated serine/threonine kinases—ensuring accurate detection of RIPK1’s active state.
· Superior Sensitivity and Versatility: Validated for WB and IF applications, enabling qualitative and quantitative analysis of RIPK1 (Ser166) phosphorylation in cell lysates, tissue sections, and immunofluorescently labeled cells—supporting diverse experimental designs in cell death and inflammation research.
· Excellent Stability and Batch Consistency: Manufactured under stringent quality control standards, the antibodies exhibit exceptional physicochemical stability and minimal inter-batch variation, delivering reliable and reproducible results across long-term research projects and cross-laboratory studies.
· Specific Marker of Necroptosis Initiation: Detects the early phosphorylation event that triggers RIPK1 recruitment to the necrosome, providing a direct readout for monitoring necroptosis initiation in response to TNF-α, pathogen infection, or other necroptotic stimuli.

Key Application Scenarios for ANT BIO PTE. LTD. Phospho-RIPK1 (Ser166) Antibodies
· TNFR1 Signaling and Cell Death Research: Detect RIPK1 (Ser166) phosphorylation to study the transition from complex I to complex II, and to distinguish between apoptotic and necroptotic cell death pathways in response to TNF-α stimulation.
· Inflammatory Disease and Tissue Injury Studies: Explore the role of RIPK1 activation in disease models such as ischemia-reperfusion injury, pancreatitis, and psoriasis, investigating how necroptosis drives inflammation and tissue damage.
· Pathogen-Host Interaction Research: Study how viruses (e.g., MCMV, HSV) or bacteria modulate RIPK1 (Ser166) phosphorylation to evade host defense mechanisms, uncovering novel host-pathogen interaction pathways.
· Drug Screening and Pharmacodynamic Evaluation: Use RIPK1 (Ser166) phosphorylation as a biomarker to screen and validate necroptosis inhibitors (e.g., Nec-1) and RIPK1 kinase inhibitors, assessing their efficacy in blocking RIPK1-mediated cell death.
· Cancer and Immunotherapy Research: Analyze abnormal RIPK1 activation in tumor cells and the tumor microenvironment, exploring its role in tumor cell survival, immune evasion, and response to immunotherapy.

ANT BIO PTE. LTD. provides comprehensive professional technical support for these antibodies, including optimized WB/IF experimental protocols, guidelines for co-localization studies with necrosome components, and one-on-one technical consultations—empowering researchers to achieve precise and reliable discoveries in RIPK1 signaling, cell death, and translational medicine.

Related Product List

Catalog Number	Product Name	Host	Conjugation	Stock Status	Price	Inquiry
S0B6410	Phospho-RIP (Ser166) Recombinant Rabbit mAb (S-2702-58)	Rabbit	Unconjugated	In stock	-	Available
S0B1435	Phospho-RIP (Ser166) Recombinant Rabbit mAb (S-1843-37)	Rabbit	Unconjugated	In stock	-	Available

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.